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1. Context
asculitis is a clinicopathological entity 
characterized by inﬂammation and ne-
crosis of  blood vessels. Antineutrophil 
cytoplasmatic autoantibodies (ANCA) are asso-
ciated with a group of  necrotizing small vessel 
vasculitides that have a paucity (pauci = few/
little) of  vascular deposition of  immunoglobulin 
and complement (1,2). Medium vessels may oc-
casionally also be involved.
2. Evidence Acquisition
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ABSTRACT
Context: Vasculitis is a clinicopathological entity characterized by inﬂammation 
and necrosis of  blood vessels.
Evidence Acquisitions: Directory of  Open Access Journals (DOAJ), Google Schol-
ar, Pubmed (NLM), LISTA (EBSCO) and Web of  Science have been searched.
Results: Two major autoantigens for ANCA are myeloperoxidase (MPO) and pro-
teinase 3 (PR3), which are proteins in the primary granules of  neutrophils and 
in the lysosomes of  monocytes. They are expressed in mature neutrophils of  
patients with ANCA, while absent in healthy subjects.
Conclusions: The kidney is the most commonly affected vital organ in ANCA-
associated vasculitis, and patient outcomes are largely determined by the severity 
of  renal disease at diagnosis and by its response to treatment.
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and Web of  Science were searched with key words 
relevant to Vasculitis, Antineutrophil cytoplasmatic 
autoantibody, Crescentic glomerulonephritis, Cha-
pel Hill Consensus Conference classiﬁcation and 
ANCA-associated small-vessel vasculitis.
3. Results 
     42 research and review articles relevant to 
this topic directly or indirectly have been found. 
From the information given in these papers, the 
following aspects were drawn out.
 Two major autoantigens for ANCA are my-
eloperoxidase (MPO) and proteinase 3 (PR3), 
which are proteins in the primary granules of  
neutrophils and in the lysosomes of  monocytes 
(2,3). They are expressed in mature neutrophils 
of  patients with ANCA, while absent in healthy 
subjects. In spite of  the fact that pauci-immune 
ANCA diseases have scanty immunoglobulin 
deposits in blood vessel walls, there is evidence 
supporting a pathogenic role for  ANCA (2,3). 
When immunoﬂuorescence on renal biopsy ma-
terial demonstrates absence of  or scanty immune 
deposition in the glomerulus, and when there are 
circulating ANCA, a diagnosis of  pauci-immune 
ANCA-associated renal vasculitis is made. In 
these cases, necrotising crescentic glomerulone-
phritis (GN) is usually found on light microscopy. 
Clinical symptoms of  systemic vasculitis could 
also be present. According to The Chapel Hill 
Consensus Conference classiﬁcation (Table 1), 
the group of  systemic small vessel vasculitides as-
sociated with ANCA  include: microscopic poly-
angiitis (MPA), Wegener’s granulomatosis (WG), 
and Churg–Strauss syndrome (4).
3.1. Pathogenesis of  ANCA-associated vasculitis
 ANCA directed to proteinase 3 (PR3-ANCA) 
or myeloperoxidase (MPO-ANCA) are strongly 
associated with the small blood vessels vasculi-
tides: MPA, WG and Churg-Strauss syndrome 
(Table 2).
 Most patients (70–80%) with WG are posi-
tive for PR3-ANCA, and few (10%) are positive 
for MPO-ANCA (Table 2). Conversely, the ma-
jority of  patients with MPA (60%) are positive 
for MPO-ANCA, and fewer (30%) are positive 
for PR3-ANCA (5). Clinical relapses coincide in 
many cases with the increase in levels of  these 
autoantibodies. Despite a relative predominance 
of   antigenic speciﬁcity for each of  the diseases, 
neither ANCA  subtype differentiates between 
the three most common phenotypes of  small 
blood vessels necrotizing vasculitis. A few pa-
tients (10%) with either WG or MPA are ANCA-
negative (6). 
 In WG, these ANCA-negative patients mostly 
have localized disease, although some of  them 
might develop ANCA once the disease progresses 
into a generalized form. In Churg–Strauss syn-
drome, only 50-65% of  patients are MPO-ANCA-
positive. In vitro, ANCA can further activate neu-
trophils to release reactive oxygen species and lytic 
enzymes, and, in conjunction with neutrophils, can 
damage and lyse endothelial cells. Patients with 
Wegener’s granulomatosis or  microscopic polyan-
gitis have an increased percentage of  neutrophils 
that constitutively express PR3 on their mem-
branes (7). These neutrophils can be stimulated by 
ANCA, without priming. Together, clinical, in vi-
tro and in vivo experimental data support a patho-
genic role for ANCA in WG and MPA, although 
this role is more evident for MPO-ANCA than for 
PR3-ANCA (8, 9). Clinical observations, includ-
ing the efﬁcacy of  B-cell depletion via rituximab 
treatment, support, but do not prove, a pathogenic 
role for ANCA in the small blood vessels vasculi-
tides. In vitro experimental studies show that the 
interplay of  ANCA, neutrophils, the alternative 
pathway of  the complement system, and endothe-
Galesic K et al
Journal of  Nephropathology, Vol 2, No 1, January 2013        www.nephropathol.com8
Table 1. The Chapel Hill Consensus Conference classiﬁcation of  vasculitis (4).
Large blood vessels vasculitis
Takayasu arteritis
Temporal arteritis
Medium-sized blood vessels vasculitis
Polyarteritis nodosa
Kawasaki disease
Central nervous system isolated angiitis
Small blood vessels vasculitis
ANCA-associated small-vessel vasculitis: Microscopic polyangiitis, Wegener’s granulomatosis, Churg–Strauss syndrome, 
Drug-induced ANCA-associated vasculitis
Immune-complex small-vessel vasculitis
Henoch–Schönlein purpura
Cryoglobulinemic vasculitis
Lupus vasculitis
Rheumatoid vasculitis
Sjögren’s syndrome vasculitis
Hypocomplementemic urticarial vasculitis
Behçet’s disease
Goodpasture’s syndrome
Serum-sickness vasculitis
Drug-induced immune-complex vasculitis
Infection-induced immune-complex vasculitis
Paraneoplastic small-vessel vasculitis
Lymphoproliferative neoplasm-induced vasculitis
Myeloproliferative neoplasm-induced vasculitis
Carcinoma-induced vasculitis
Inﬂammatory bowel disease vasculitis
Table 2.  The prevalence of  antineutrophil cytoplasmatic autoantibodies (ANCA) in small blood vessels vasculitis (5).
VASCULITIS PR3-ANCAa
(C-ANCA,  %)
MPO-ANCAb
(P-ANCA, %)
NEGATIVE
ANCA
Wegener’s granulomatosis 75 20 5
Microscopic polyangiitis 40 50 10
Churg-Strauss syndrome 10 60 30
Microscopic polyangiitis limited to kidney 20 70 10
a PR3 = proteinase 3; b MPO=myeloperoxidase
Table 3. The renal changes in patients with vasculitis.
VASCULITIS PATIENTS WITH RENAL 
DISEASE (%)
GLOMERULONEPHRI-
TIS
RENAL VESSELS LE-
SIONS (%)
Microscopic polyangiitis 80-90 present 15-35
Wegener’s granulomatosis 75-85 present 8
Churg-Strauss syndrome 25-40 present rare
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lial cells could result in lysis of  the endothelium 
(9). Several animal models of  ANCA disease have 
been described that are pathologically identical to 
human ANCA disease (10,11).  Finally, microbial 
factors, in particular Staphylococcus aureus and 
gram-negative bacteria, seem to be involved in dis-
ease induction and expression, but further studies 
are needed to deﬁne their precise role in disease 
development (11). 
 Pauci-immune necrotizing and crescentic GN 
is a frequent component of   ANCA  disease. The 
pathological and immunological features of  GN 
are similar in different clinicopathologic variants 
of  ANCA diseases, including granulomatosis with 
polyangiitis (WG), MPA, Churg-Strauss syndrome 
and renal-limited pauci-immune necrotising cres-
centing glomerulonephritis (Table 3, ref  12,13). 
3.2. Renal features
 The kidney is the most commonly affected 
vital organ in ANCA-associated vasculitis, and 
patient outcomes are largely determined by the 
severity of  renal disease at diagnosis and by its 
response to treatment. In an elderly patient, 
ANCA-associated renal vasculitis is the most 
common cause of  acute renal failure with nor-
mal sized kidneys without an obvious precipitant 
(1,2). The manifestations of  ANCA disease can 
be limited to the kidney alone, or may involve 
upper respiratory tract, the lungs, the skin, or a 
number of  other organs in various combinations 
(12,13). 
 ANCA-associated pauciimmune glomerulo-
nephritis is more common cause of  rapidly pro-
gressive glomerulonephritis and death as com-
pared with immune complex rapidly progressive 
glomerulonephritis or anti-glomerular basement 
membrane (GBM) disease (14,15).  Rapidly pro-
gressive glomerulonephritis is the most frequent 
clinical manifestation of  ANCA-associated glo-
merulonephritis, although the syndromes of  as-
ymptomatic hematuria with minimal amounts 
of  proteinuria or acute nephritis are possible as 
well. Renal disease is manifested by hematuria 
with dysmorphic red blood cells and red blood 
cells casts in urine sediment, while proteinuria is 
usually moderate (2–3 g/day). At least 50% of  
patients with ANCA-associated glomerulone-
phritis have pulmonary disease. Massive pulmo-
nary hemorrhage affects about 10% of  patients 
with ANCA glomerulonephritis, and is associ-
ated with an elevated risk of  death (16). Consti-
tutional signs and symptoms, such as fever, my-
algias, arthralgias, and malaise, often accompany 
small-vessel vasculitis. Many patients describe a 
“ﬂulike” syndrome early in the course of  their 
disease. Arthralgias are migratory and affect both 
small and large joints, with evidence of  synovitis 
in small number of  patients. Vessels in the skin, 
respiratory tract, kidneys, gut, peripheral nerves, 
and skeletal muscle are often involved, but the 
frequencies vary among different phenotypes of  
small blood vessel vasculitis (2,7). 
 The typical renal biopsy feature in ANCA-as-
sociated renal vasculitis is pauci-immune necro-
tizing glomerulonephritis with crescents forma-
tion. The lesions are focal or diffuse, with scanty 
or absent glomerular staining for immunoglobu-
lin by immunoﬂuorescence microscopy (17). The 
extensive histologic analysis of  MPO-ANCA 
positive, PR3-ANCA positive, and ANCA-nega-
tive kidney biopsies showed that there was no sig-
niﬁcant difference in the main glomerular lesions, 
tubular as well as interstitial histologic features 
between these three groups (1,2,3). By deﬁnition, 
in ANCA-associated renal vasculitis, immune de-
posits are absent or scanty and scattered, hence 
the term pauci-immune glomerulonephritis. In-
stead, the ﬁbrinogen antiserum strongly stains 
areas of  necrosis of  the tuft and ﬁbrin deposits 
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into the crescents (Figure 1).  A focal form of  
crescentic GN is reported more frequent than 
diffuse in ANCA-associated renal vasculitis. On 
electron microscopy examination absence of  or a 
few electron-dense immune deposits is the main 
ﬁnding. Some 5% of  ANCA-associated renal vas-
culitis patients present with simultaneous renal 
vasculitis and anti-GBM disease. These patients 
are older, have more severe renal disease and are 
more likely to have pulmonary involvement than 
just ANCA-associated renal vasculitis.
Figure 1. Necrotizing ANCA glomerulonephritis with cel-
lular and ﬁbrocellular crescents (microscopic polyangiitis).
A glomerulus shows segmental necrosis with small cellular 
and ﬁbrocellular crescent formation. The non-necrotic seg-
ments are histologically unremarkable. There is interstitial 
inﬂammation, including tubulitis (PAS, x400).
 In vasculitis, the Birmingham Vasculitis Ac-
tivity Score (BVAS) (18) and other similar scores 
have been applied to assess disease activity, 
whereas the Vasculitis Damage Index (DVI, 19) 
provides information on disease damage. The 
BVAS has also been shown to have prognostic 
value, at least in short to medium term mortality, 
which makes clinical sense (18).
3.2.1. Microscopic polyangiitis (MPA)
 Microscopic polyangiitis (MPA) is a necro-
tizing angiitis involving capillaries, venules, and 
arterioles of  one or more organs either simulta-
neously or at different times, including the kid-
neys, lungs, skin, spleen, liver, heart, and muscle 
(2,7,15). 
Typically, there are MPO-ANCA (Table 1) and it 
shows similar organ involvement as WG, but the 
symptoms of  the upper respiratory tract are usu-
ally milder in MPA. In MPA there is no granulo-
matous inﬂammation, which is usually present in 
WG. The recurrence is rare in patients with MPA.
3.2. 2.Renal limited MPA 
 The presence of  only general systemic symp-
toms such as fever, with renal features, is highly 
suggestive of  renal limited vasculitis. In this dis-
ease there is no respiratory disease or any other 
organ involvement.
3.2.3. Granulomatosis with polyangiitis (WG)
 Granulomatosis with polyangiitis has been re-
cently accepted as an alternative name for WG 
(5). WG is a necrotizing vasculitis of  the small 
and medium-sized vessels, associated with granu-
lomatous inﬂammation of  upper and lower re-
spiratory tract and the frequent ﬁnding of  glo-
merulonephritis. In active disease in about 90% 
of  cases PR3-ANCA are found (Table 1). The 
risk of  relapse is not uniform among all patients 
with ANCA vasculitis. An increased risk of  re-
lapse has been associated with a diagnosis of  WG 
(as opposed to MPA). Relapses in the kidney are 
heralded by the recurrence of  microscopic he-
maturia, red blood cell casts, and worsening renal 
function. Fluctuations in the amount of  protein-
uria are not good indicators of  active disease, and 
are related to glomerulosclerosis.
3.2.4. Churg-Strauss syndrome
 Rarely presenting as rapidly progressive glo-
merulonephritis, Churg-Strauss syndrome is 
diagnosed when asthma, allergic rhinitis and 
increased circulating eosinophils are present. 
MPO-ANCA can be detected in up to 60% of  
cases (Table 1) Renal involvement is seen in ap-
proximately 25% of  patients. (5,7). Depending 
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Figure 2. Treatment of   ANCA-associated vasculitis.
on the timing of  renal biopsy, glomeruli can be 
affected by active lesions or by more sclerotic 
alterations. It is not infrequent to observe both 
types of  lesions in the same renal biopsy and 
even in the same glomerulus.
3.3. Treatment 
 Treatment for vasculitis requires induction of  re-
mission and remission maintenance therapy (Table 4).
 When the natural history of  WG was de-
scribed in 1958, it was usually a fatal disease 
without effective treatment and patient survival 
after diagnosis averaged 5 months. The introduc-
tion of  glucocorticosteroids (GC) in the 1960s 
extended average survival only by 8 months (5). 
This changed radically when Fauci and Wolff  
pioneered the use of  cyclophosphamide in the 
early 1970s (20). The administration of  daily oral 
cyclophosphamide (1-2 mg/kg) and prednisone 
(1mg/kg) resulted in a dramatic clinical beneﬁt. 
Prednisone was tapered and discontinued with-
in 6 to 9 months, while cyclophosphamide was 
maintained at least for a year.
3.4.1. Induction therapy
Table 4. Induction of  remission therapy in ANCA-
associates vasculitis
INDUCTION OF REMISSION
1. Glucorticoids – 3 intravenous pulses (0.5-1g/day) fol-
lowed by 1mg/kg/day orally for 3-6 months
2. Cyclophosphamide – 1-2mg/kg/day orally for 3-6 
months
3. Plasmapheresis – in patients presenting with pulmo-
nary hemorrhage (A) and/or severe renal disfunction (B)
 
 The treatment of  renal vasculitis involves 
the use of  high dose GC in combination with 
cyclophosphamide to induce remission of  dis-
ease (21,22). This treatment is the “standard 
of  care“for renal vasculitis. The duration of  in-
duction therapy is 3-6 months (ﬁgure 2). In the 
presence of  kidney failure, plasma exchange 
(plasmapheresis) is often used in addition to 
pharmacological treatment (16,21,22). Once re-
mission is achieved, treatment is scaled back to 
maintenance therapy with lower doses of  GC, 
while cyclophosphamide is replaced by a less tox-
Galesic K et al
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ic immunosuppressant, such as azathioprine.
 Daily oral cyclophosphamide plus GC sub-
stantially advanced the treatment of  general-
ized WG and remains the gold standard ther-
apy. Cyclophosphamide can be given as a daily 
oral dose or as intermittent oral or intravenous 
pulses and is continued for 3-6 months. Intra-
venous regimens tend to give a lower total dose 
and have fewer side effects, but may later give a 
higher rate of  relapse (23). In patients receiving 
intravenous cyclophosphamide pulse therapy, 
antiemetic drugs  must be given immediately be-
fore and some hours after treatment. At least 3 
liters of  ﬂuid must be administered on the day 
of  cyclophosphamide treatment (21,22). The cy-
clophosphamide dose has to be adjusted to the 
peripheral leukocyte count, which is at a mini-
mum of  3,000/μl.  Studies have found remission 
rates between 70% and 100% and early mortality 
rates of  less than 10% with increased treatment-
related morbidity (21,22). Therefore, research 
centered on searching for equally effective but 
safer treatments, including changing the route of  
administration and dosage of  cyclophosphamide 
and testing a monthly intravenous regimen. A 
few nonrandomized studies demonstrated simi-
lar rates of  remission induction with intermittent 
intravenous cyclophosphamide as those using the 
daily oral drug (21). The advantage of  the intra-
venous route is the smaller cumulative dosage 
and, therefore, fewer adverse events. Three ran-
domized trials have compared the effectiveness 
and security proﬁle of  pulsed cyclophosphamide 
with daily oral administration for remission in-
duction (20,23,24). A meta-analysis that summa-
rized the results from these trials concluded that 
pulsed cyclophosphamide is as effective as daily 
oral cyclophosphamide with much less severe 
toxic effects, yet possibly with a higher relapse 
rate (21). 
 The European Vasculitis Study Group (EU-
VAS) devised a randomized trial comparing the 
efﬁcacy of  oral cyclophosphamide (2 mg/kg per 
day) with intravenous pulsed cyclophosphamide 
(15 mg/kg every 2 weeks for the ﬁrst 3 pulses 
and every 3 weeks thereafter) with the same GC 
regimen in both groups, (CYCLOPS study). The 
study included 149 patients with generalized 
ANCA-associated vasculitis with renal involve-
ment with vital organ manifestations. Preliminary 
results show that pulsed cyclophosphamide is 
equally effective as oral cyclophosphamide for re-
mission induction (25). Unexpectedly, there were 
no differences in severe adverse events or deaths 
between groups. 
 Patients receiving pulse cyclophosphamide 
should also be given oral or intravenous 2-mer-
captoethanesulfonate sodium (mesna) which 
binds to acrolein, a toxic metabolite of  cyclophos-
phamide, making it less toxic for urothelial ep-
itelium. Mesna may also be beneﬁcial in patients 
receiving continuous oral cyclophosphamide. 
Determining the optimum mode (oral versus 
intravenous) and duration of  treatment with cy-
clophosphamide depends on several factors and 
considerations. The short and long-term compli-
cations associated with the use of  cyclophospha-
mide are commensurate with the cumulative dose 
received. In general, the intravenous regimen al-
lows for a two to three times smaller total dose 
of  cyclophosphamide than the oral regimen. In 
prospective and retrospective analyses, intrave-
nous therapy was associated with a signiﬁcant 
decrease in the rate of  clinically signiﬁcant neu-
tropenia and other complications. The optimum 
length of  therapy with cyclophosphamide has 
not been determined and is the subject of  ongo-
ing discussion. GC and cyclophosphamide based 
treatements have a long-term remission rate of  
between 60% and 92%. In patients achieving 
 www.nephropathol.com     Journal of  Nephropathology, Vol 2, No 1, January 2013 
Treatment of   ANCA-associated vasculitis
13
complete remission within 6 months of  therapy, 
treatment can be stopped with the institution of  
close patient follow-up. In those individuals with 
persistently active disease at 6 months, it is rea-
sonable to continue cyclophosphamide therapy 
for a full 12 months. An alternative regimen con-
sists of  switching cyclophosphamide to oral aza-
thioprine at the end of  3 months if  the patient is 
in remission. Azathioprine is then continued for 
18 months. This regimen offers the advantage of  
a limited use of  cyclophosphamide and results in 
rates of  remission and relapses similar to the cy-
clophosphamide only-based therapies. 
 Patients presenting with pulmonary hemor-
rhage beneﬁt also from the institution of  plas-
mapheresis in a regimen similar to that used 
for patients with Goodpasture’s disease or anti-
GBM disease (16). Plasmapheresis is typically 
performed daily until the pulmonary hemor-
rhage ceases and then every other day for a to-
tal of  seven to ten treatments. The addition of  
plasma exchange to cyclophosphamide and GC 
also improves the chances of  renal function re-
covery in patients with severe renal dysfunction 
(serum creatinine≥500μmol/L) or needing di-
alysis at presentation. For patients without severe 
renal failure or without pulmonary hemorrhage, 
controlled and observational trials have not dem-
onstrated a beneﬁcial role of  the addition of  
plasmapheresis to cyclophosphamide and GC 
(16,26,27,28).
 Other therapies, like the inhibitors of  lym-
phocyte proliferation mycophenolatic acid salts 
(mycophenolate mofetil or sodium mycopheno-
late) and leﬂunomide, the B cell-depleting chime-
ric antibody rituximab, methotrexate, anti-CD52 
therapy and intravenous immunoglobulin have 
been suggested but their place is not yet clear.
 Methotrexate has been evaluated as an alter-
native to cyclophosphamide for the induction of  
remission in a randomized, controlled trial that 
revealed a remission rate at 6 months of  89.8% 
in patients receiving methotrexate, which was 
not inferior to that in patients treated with cy-
clophosphamide, which was 93.5% (29). Relapse 
rates at 18 months were signiﬁcantly more fre-
quent in the methotrexate group (69.5%) than in 
the cyclophosphamide group (46.5%, p=0.023). 
The dose of  methotrexate should be decreased 
by 50% in patients with renal insufﬁciency and its 
use is contraindicated if  the creatinine clearence 
is < 10mL/minute. Trimethoprim-sulfamethox-
azole (TMP-SMX) for prophylaxis against Pneu-
mocystis jiroveci (carinii) pneumonia cannot be 
used concomitantly with methotrexate. 
 Two randomized controlled trials examined 
rituximab as a ﬁrst-line induction therapy for 
ANCA vasculitis (RITUXIVAS and RAVE trial; 
30,31). Rituximab showed equivalent efﬁcacy to 
cyclophosphamide in induction therapy and the 
evidence didn’t show any difference in rates of  
adverse effects. Rituximab can be recommanded 
for remission induction when cyclophosphamide 
is contraindicated (for example, in infectioous dis-
ease, intolerance or strong desire to avoid its use). 
3.3.2.Practical recommendations
 Pulse cyclophosphamide with oral GC can be 
used to induce remission in patients with general-
ized organ-threatening disease.  Patients should 
be started with 1mg/kg per day of  oral predni-
sone, and tapered progressively over 3–4 months 
plus intravenous pulse cyclophosphamide (every 
3 weeks for 6 months). Intravenous methylpred-
nisolone (0.5 to 1.0 g/day for 3 days) can be con-
sidered in the beginning of  the treatement. Pred-
nisone should be tapered to 10 mg at 6 months 
and maintained at this dose until month 15, when 
it should be tapered to 7.5mg and  maintained for 
at least 3 more months followed by local practice. 
Cyclophosphamide doses should be adjusted by 
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age, renal function, and leukocyte count. 
Patients presenting with pulmonary hemorrhage 
and severe renal failure also beneﬁt from the in-
stitution of  plasmapheresis.
 TMP-SMX has been used in WG mainly to 
prevent the occurrence of  Pneumocystis jiroveci 
(carinii) infection, upper respiratory tract infec-
tion and subsequent relapse of  disease (21,22). 
Rituximab shows equivalent efﬁcacy to cyclo-
phosphamide in induction therapy and may be 
superior in relapsing disease.
3.3.3.Maintenance  therapy
Table 5. Maintenance  therapy of  ANCA-associated 
vasculitis.
MAINTENANCE THERAPY
1. Glucocorticoids – prednisolone 40-60mg/day orally, 
with dose tapering for at least 12 (usually 24) months
2. Azathioprine – 2mg/kg/day bid; should be started 
when cyclophosphamide is discontinued; after 6 months 
reduced to 1.5mg/kg/day bid and maintained for 6 
months more
 The goal of  the maintenance therapy is the 
prevention of  disease relapses. Disease relapses 
occur in 75% of   WG and in 50% of  MPA cases 
by 5 years (Table 5). The combination of  azathio-
prine and daily prednisone effectively maintains 
remission. Azathioprine has equivalent efﬁcacy 
as a maintenance agent to cyclophosphamide 
with fewer episodes of  leukopenia. Remission 
maintenance therapy should be continued for at 
least 2 years especially in WG (21,22). Two mil-
ligrams per kilogram of  azathioprine should be 
started when cyclophosphamide is discontinued 
and after 6 months it should be reduced to 1.5 
mg/kg per day and maintained for at least 6 more 
months. The role of  azathioprine in the mainte-
nance therapy in patients with ANCA vasculitis 
was examined as an alternative to a prolonged 
course of  cyclophosphamide (32). Patients were 
treated with standard induction therapy of  cy-
clophosphamide 2mg/kg/day and prednisolone 
1mg/kg/day. At remission, 144 patients were 
randomised to either azathioprine 2mg/kg/day 
and prednisolone 10mg/day or continued cyclo-
phosphamide 1.5mg/kg/day until 12 months, 
after which all patients were treated with azathio-
prine 1.5mg/kg/day and prednisolone 7.5mg/
day. At the end of  12 months of  follow-up, the 
risk of  relapse was not signiﬁcantly different be-
tween the two groups and there was not a sig-
niﬁcant difference in the rate of  adverse events, 
except that leukopenia was signiﬁcantly less likely 
with azathioprine. This was not reﬂected in an 
increase in infectious complications in patients 
on cyclophosphamide. Azathioprine allergy or 
intolerance occurs in 5-10% and testing for thio-
purine s-methyltransferase activity identiﬁes rare 
patients at risk of  severe myelosupression. Hy-
persensitivity reaction occurs within 2-3 weeks of  
commencing azathioprine therapy. 
 Several other agents have been evaluated in a 
limited way as adjunctive or maintenance therapy 
for ANCA vasculitis. These include the inhibi-
tors of  lymphocyte proliferation mycophenolate 
acid salts and leﬂunomide, the B cell-depleting 
chimeric antibody rituximab, blockers of  the tu-
mor necrosis factor (TNF)-α pathway inﬂiximab 
and etanercept. The possible role of  etanercept 
for the maintenance of  remission was evaluated 
in a randomized, placebo-controlled trial of  180 
patients in the Wegener’s Granulomatosis Etaner-
cept Trial (WGET) (33). In addition to etanercept 
or placebo, patients received standard therapy 
with glucocorticoids plus cyclophosphamide or 
methotrexate. After 3–6 months of  cyclophos-
phamide, patients in remission discontinued cy-
clophosphamide and were treated with etanercept 
and either methotrexate or azathioprine (depend-
ing on their degree of  renal insufﬁciency). Over 
a mean follow up of  27 months, 72% of  patients 
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attained a sustained remission, but only 50% of  
patients remained in remission for the remainder 
of  the trial. There were no signiﬁcant differences 
between the etanercept and control groups in the 
rates of  sustained remission, in the relative risk of  
disease ﬂares per 100 person-years of  follow-up, 
or in the severity of  relapses. During the study, 
56.2% of  patients in the etanercept group and 
57.1% of  those in the control group had at least 
one severe or life threatening adverse event or 
died. Solid cancers developed in six patients in 
the etanercept group, as compared with none in 
the control group (P=0.01). It was concluded that 
etanercept was not effective for the maintenance 
of  remission in patients with WG (33). 
 Whether methotrexate is effective in prevent-
ing relapses after induction therapy with cyclo-
phosphamide has also been evaluated in open-
label, multicenter trial (34). 159 eligible patients 
who entered remission received azathioprine or 
methotrexate. The two agents appear to be simi-
lar alternatives for maintenance thrapy in patients 
with WG and MPA after initial remission (34). 
Leﬂunomide has been shown to be superior to 
methotrexate for the prevention of  relapse in 
WG (35) and mycophenolate mofetil was less ef-
fective than azathioprine for the prevention of  
relapses in ANCA vasculitis after cyclophospha-
mide induction therapy (36). 
3.3.4.Practical recommendations
 The combination of  azathioprine and daily 
prednisone effectively maintains remission. Two 
milligrams per kilogram of  azathioprine should 
be started when cyclophosphamide is discontin-
ued. At 6 months azathioprine should be reduced 
to 1.5 mg/kg per day and maintained for at least 6 
more months. Azathioprine is the preferred main-
tenance immunosupressive agent. Methotrexate 
is indicated for maintenance therapy in patients 
intolerant of  azathioprine.
3.4.5.Treatment of  relapse
 Relapse is initially manifested by a return or 
increase in haematuria and proteinuria with dete-
rioration of  renal function and is usually associat-
ed with ANCA appearance and raised inﬂamma-
tory markers. Repetead renal biopsy is indicated 
if  there is uncertainity as to whether or not renal 
relapse is occurring. Such relapses are treated by 
a return to an induction protocol with cyclophos-
phamide or rituximab. Severe relapses should be 
treated with cyclophoshamide, GC and plasma-
pheresis. When renal vasculitis has caused renal 
impairement a response to therapy is indicated 
by an improvemenet in serum creatinine, usu-
ally within the ﬁrst 2 weeks. Renal function then 
usually continues to improve for 6-12 months. 
For dialysis-dependent patients at presentation, 
recovery is usually seen within 2-3 weeks, but 
sometimes it can occur later (37, 38). 
3.4.6.Response to treatment
 Patients treated with either intravenous or oral 
cyclophosphamide have a long-term remission rate 
of  between 60% and 92%. Based on a large ob-
servational ‘’cohorts’’ of  patients with ANCA 
vasculitis, female gender, black race, and poten-
tially older age were associated with a higher 
likelihood of  treatment resistance. Patients with 
PR3-ANCA may have a better chance of  remis-
sion than patients with MPO-ANCA (39, 40). 
3.4.7. Refractory disease
 Cyclophosphamide and GC are generally 
considered standard induction therapy for AN-
CA-associated vasculitis (Table 6). However, a 
subset of  patients are refractory or intolerant 
to this treatment (37).  New therapeutic ap-
proaches ‘’include’’ rituximab, a chimeric anti-
CD20 antibody, which has emerged as a main 
therapy for refractory vasvulitis (38, 39, 40). Cu-
mulative data from several open studies on the 
treatment of  ANCA-associated MPA suggest 
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that in the vast majority of  cases rituximab has 
a beneﬁcial effect. Two randomized controlled 
trials conﬁrmed these promising results, sug-
gesting that rituximab might be considered even 
as an option for the ﬁrst-line induction therapy 
in ANCA-associated vasculitis, and providing an 
additional tool for treating patients with disease 
relapse after previous therapy. While rituximab 
is very effective in the depletion of  B cells, cur-
rent research suggests it could also inﬂuence 
other immune system cells and reestablish im-
mune homeostasis and tolerance. The safety 
proﬁle of  rituximab reveals that most reactions 
are infusion-related and that the incidence of  
serious side effects is low. Systemic infection re-
mains a major concern and may result in death. 
A small number of  cases of  progressive multi-
focal leukoencephalopathy reported in patients 
receiving rituximab in off-label use (albeit none 
with ANCA-associated vasculitis) highlights the 
importance of  pharmacovigilance.
3.3.8. Supportive therapy
 Special effort must be exercised to minimize 
the short- and long-term complications of  treat-
ment with GC and cyclophosphamide of  AN-
CA-associated vasculitis. When GC are used, the 
development of  osteoporosis can be minimized 
with the early institution of  calcium and vita-
min D supplementation, while in patients with 
established osteoporosis, calcitonin or bisphos-
phonates (if  not contraindicated by azotemia or 
esophagitis) are considered.
 Rigorous control of  blood pressure with so-
dium restriction and antihypertensive therapy is 
essential to minimize the additive effect of  hy-
pertension in loss of  renal function, following 
active nephritis. Hormonal manipulation during 
cytotoxic therapy may allow the preservation of  
gonadal function. 
Table 6. Criteria for treatment response
A) Complete remission
The absence of  symptoms or signs attributable to active 
vasculitis, with a Birmingham Vasculitis Activity Score of  
0-1 (18). The absence of  renal disease activity was indi-
cated by stable or falling creatinine levels and the absence 
of  erythrocyte cell casts. The results of  ANCA testing 
were not used as criteria for remission or partial remis-
sion. Persistence proteinuria was not considered indica-
tive of  persistence of  disease activity.
B) Partial remission 
Clear-cut suppression of  the disease, with improvement 
or stopping in disease progresion and stabilization of  re-
nal function
C) Treatment resistance
(1) progressive decline in renal function with the persis-
tence of  an active urine sediment, or 
(2) persistence or new appearance of  any extrarenal 
manifestation of  vasculitis despite immunosuppressive 
therapy
D) Relapse
The re-emergence of  clinical symptoms attributable to 
vasculitis or worsening of  original manifestations after 4 
weeks of  complete clinical remission had been achieved 
or occurrence of  at least one of  the following: 
(1) rapid rise in serum creatinine accompanied by an ac-
tive urine sediment, 
(2) a renal biopsy demonstrating active necrosis or cres-
cent formation,
(3) active vasculitis of  respiratory tract (hemoptysis), pul-
monary nodules without evidence for infection,
(4) active vasculitis of  gastrointestinal ‘’tract’’,
(5) iritis or uveitis,
(6) new mononeuritis multiplex,
(7) necrotizing vasculitis identiﬁed by biopsy in any tissue
3.3.9. Prognosis and prognostic factors
 Untreated, systemic vasculitis is associat-
ed with an year mortality. The introduction of  
GC, cyclophosphamide and azathioprine led to 
a marked improvement in survival to 84% and 
76% at 1 and 5 years, respectively. Predictors of  
death include increased age and creatinine at pre-
sentation, disease extent and severity at diagnosis, 
pulmonary haemorrhage, and treatment-related 
infection (5,7,41,42). 
 Several studies have examined the question of  
prognostic factors in ANCA associated vasculitis. 
The presence of  pulmonary hemorrhage was the 
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most important determinant of  patient survival, 
whereas other pulmonary ﬁndings (eg, inﬁltrates, 
nodules, or cavities) did not increase the risk of  
death. The risk of  end stage renal disease is large-
ly determined by the degree of  renal dysfunc-
tion at the time of  diagnosis. Serum creatinine 
is the single most important prognostic marker 
for long-term renal outcome as exempliﬁed by a 
1.24-fold increased risk for end stage renal disease 
for each 1 mg/dL increase in serum creatinine at 
baseline. Nevertheless, there is no threshold of  
renal dysfunction below which treatment is futile, 
as remission occurs in 57% of  individuals with an 
estimated GFR<10mL/minute. Histopathologic 
features of  chronic renal scarring (glomerulo-
sclerosis, interstitial ﬁbrosis and tubular atrophy) 
have consistently been associated with poor renal 
outcomes.  A high proportion of  normal glom-
eruli, glomeruli with active crescents and acute 
tubular necrosis in the renal biopsy are predictors 
of  a good renal outcome. The impact of  renal 
damage as a predictor of  resistance emphasizes 
the importance of  early diagnosis and prompt in-
stitution of  therapy (41,42).
 Recurrence of  ANCA vasculitis after renal 
transplantation occurs in about 20% of  patients. 
Time to recurrence varies widely, from a few days 
to several years post transplantation. Patients with 
WG appear more likely to relapse than patients 
with MPA or necrotizing crescentic glomerulone-
phritis alone, whereas the transplantation should 
be delayed in patients with active disease. In the 
majority of  reported cases, recurrent disease after 
transplantation responded well to treatment with 
cyclophosphamide and GC pulses.
4. Conclusions
 Vasculitis is a clinicopathological entity char-
acterized by inﬂammation and necrosis of  blood 
vessels. Antineutrophil cytoplasmatic autoanti-
bodies (ANCA) are associated with a group of  
necrotizing small vessel vasculitides that have a 
paucity of  vascular deposition of  immunoglobu-
lin and complement. The kidney is the most com-
monly affected vital organ in ANCA-associated 
vasculitis, and patient outcomes are largely deter-
mined by the severity of  renal disease at diagnosis 
and by its response to treatment.
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